Article
With 6 rivals in the U.S., why would Lilly shell out up to $1B for Innovent's P
Rating:
0.0
Views:
88
Likes:
1
Library:
1
Eli Lilly, on the heels of detailing a clinical win in China for PD-1 inhibitor Tyvyt, has decided to take a bigger stake in the drug developed by partner Innovent Biologics. But if approved in the U.S., Tyvyt would face some entrenched competitors—and even more rivals could be on their way.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value